← Leaderboards
Karin L Gaensler
University Of California San Francisco
$8,072,507
Attributed
$8,072,507
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$8,072,507 · 8
By mechanism
R01$6,651,133 · 4
R21$780,951 · 2
P01$407,556 · 1
P60$232,867 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Elliott P Vichinsky$12,339,152
- Mark A Israel$17,072,281
- Sylvia T Singer$2,056,881
- Kevin M Shannon$44,683,939
- James Louis Rubenstein$5,966,949
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionGene TherapyCellsVectorBaseImmune ResponseT-LymphocyteIn VivoMediatingTransduction EfficiencyGenesGene TransferMorbidity - Disease RateTherapeutic GeneNeonateAnimalsHereditary DiseaseMortality Vital StatisticsHematopoietic Stem CellsLaboratory MouseAntigensTissuesImmuneAllogenic
Grant awards (28)
Lentivirus-based positive/negative selection in minimally ablative transplants$576,603
R01 · FY2015 · HL · contact PI
Lentivirus-based positive/negative selection in minimally ablative transplants$594,263
R01 · FY2014 · HL · contact PI
Efficacy and safety of novel CD80 IL15 IL15Ra expressing autologous AML vaccines$167,155
R21 · FY2014 · CA · contact PI
Lentivirus-based positive/negative selection in minimally ablative transplants$576,963
R01 · FY2013 · HL · contact PI
Efficacy and safety of novel CD80 IL15 IL15Ra expressing autologous AML vaccines$202,511
R21 · FY2013 · CA · contact PI
Lentivirus-based positive/negative selection in minimally ablative transplants$633,576
R01 · FY2012 · HL · contact PI
Neonatal Chemoselection Following Ex Vivo Gene Transfer For Hereditary Disorders$382,388
R01 · FY2012 · HL · contact PI
Neonatal Chemoselection Following Ex Vivo Gene Transfer For Hereditary Disorders$386,250
R01 · FY2011 · HL · contact PI
Neonatal Chemoselection Following Ex Vivo Gene Transfer For Hereditary Disorders$386,250
R01 · FY2010 · HL · contact PI
Tolerance Induction by Neonatal Gene Delivery$298,375
R01 · FY2010 · DK · contact PI
Neonatal Chemoselection Following Ex Vivo Gene Transfer For Hereditary Disorders$386,250
R01 · FY2009 · HL · contact PI
Tolerance Induction by Neonatal Gene Delivery$301,389
R01 · FY2009 · DK · contact PI
Neonatal Chemoselection Following Ex Vivo Gene Transfer For Hereditary Disorders$386,042
R01 · FY2008 · HL · contact PI
Tolerance Induction by Neonatal Gene Delivery$301,145
R01 · FY2008 · DK · contact PI
Tolerance Induction by Neonatal Gene Delivery$306,296
R01 · FY2007 · DK · contact PI
Tolerance Induction by Neonatal Gene Delivery$313,650
R01 · FY2006 · DK · contact PI
In Vivo Stem Cell Selection in Neonatal Allo-Transplants$221,910
R21 · FY2006 · DK · contact PI
In Vivo Stem Cell Selection in Neonatal Allo-Transplants$189,375
R21 · FY2005 · DK
SEQUENTIAL PRE AND POSTNATAL GENE THERAPY OF HEMOPHILIA$282,033
R01 · FY2002 · HL
GENE TRANSFER TO FETAL AND NEONATAL HSC POPULATIONS$135,852
P01 · FY2002 · HL
CIS-ACTING ELEMENTS THAT REGULATE EXPRESSION OF THE BETA-GLOBIN GENE FAMILY$0
P60 · FY2002 · HL
CIS-ACTING ELEMENTS THAT REGULATE EXPRESSION OF THE BETA-GLOBIN GENE FAMILY$0
P60 · FY2002 · HL
SEQUENTIAL PRE AND POSTNATAL GENE THERAPY OF HEMOPHILIA$273,818
R01 · FY2001 · HL
GENE TRANSFER TO FETAL AND NEONATAL HSC POPULATIONS$135,852
P01 · FY2001 · HL
CIS-ACTING ELEMENTS THAT REGULATE EXPRESSION OF THE BETA-GLOBIN GENE FAMILY$0
P60 · FY2001 · HL
SEQUENTIAL PRE AND POSTNATAL GENE THERAPY OF HEMOPHILIA$265,842
R01 · FY2000 · HL
CIS-ACTING ELEMENTS THAT REGULATE EXPRESSION OF THE BETA-GLOBIN GENE FAMILY$232,867
P60 · FY2000 · HL
GENE TRANSFER TO FETAL AND NEONATAL HSC POPULATIONS$135,852
P01 · FY2000 · HL